🇺🇸 FDA
Pipeline program

Gazyvaro 1,000 mg concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg hard capsules, Venclyxto 10 mg film-coated tablets, Calquence 100 mg hard capsules

D8220C00027

Phase 3 small_molecule active

Quick answer

Gazyvaro 1,000 mg concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg hard capsules, Venclyxto 10 mg film-coated tablets, Calquence 100 mg hard capsules for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials